“It should be the function of medicine to have people die young as late as possible.”

        —Ernest L Wynder

• Diabetes treatment for CVD reduction is categorized in two arms, i.e., SGLT2 inhibitors and GLP-1R antagonists with hemodynamic effect and anti-atherogenic effect mechanism of action respectively.
• SGLT2 inhibitors improve ventricular loading conditions (diuresis, natriuresis, etc.), myocardial energetics, TGF, IGH, etc. by modulating SNS activity.
• GLP-1R on the other hand has anti-inflammatory effects, reduces oxidative stress, inhibits RAAS, increases natriuresis, etc.
• SGLT2 inhibitors and GLP-1R provide complete CV renal protection combined and are a challenge.